Sudden gains and large intersession improvements in internet-based psychodynamic treatment (IPDT) for depressed adolescents

Figures & data

Table I. Demographic data at baseline.

Demographics:	SG (n = 17)		Non-SG (n = 49)		LII (n = 34)		Non-LII (n = 32)
	n/M	%/SD	n/M	%/SD	n/M	%/SD	n/M	%/SD
Female	14	82.4	41	83.7	29	85.3	26	81.3
Gender identity uncertain/other	1	5.9	2	4.1	2	5.9	1	3.1
Age	16.65	1.27	16.61	1.06	16.74	1.19	16.60	1.02
Major depressive disorder^a	17	100	49	100	34	100	32	100
Any anxiety disorder^a	12	70.6	27	55.1	22	64.7	17	53.1
PTSD^a	2	11.8	2	4.1	4	11.8	0	0
Eating disorder^ab	0	0	3	6.1	1	2.9	2	6.3
QIDS-A17-SR pre-treatment	14.06	5.03	14.73	4.16	14.65	4.84	14.47	3.89
MADRS-S pre-treatment	23.59	9.91	26.61	6.53	25.21	8.18	26.50	6.96
GAD-7 pre-treatment	11.24	5.13	11.8	3.80	11.62	4.26	11.69	4.09

Note. QIDS-A17-SR = Quick inventory of depressive symptomatology adolescent self-rated version; MADRS-S = Montgomery Åsberg Depression Rating Scale–self-rated; GAD-7 = Generalized Anxiety Disorder 7-item scale. No significant between-group differences on any of the data at the baseline. ^aConfirmed by the MINI-International Neuropsychiatric Interview at baseline of the RCT. ^bBulimia nervosa/Binge-eating disorder.

Table II. Observed means, standard deviations, and number of observations for outcome and processes over the treatment period.

Measure	Week
	0	1	2	3	4	5	6	7	8	9
QIDS-A17-SR
M	14.56	14.48	13.55	12.89	12.13	11.78	11.94	11.60	10.59	9.46
SD	4.37	3.76	4.6	4.52	4.14	4.20	4.31	4.60	5.02	4.98
n	66	66	65	57	55	55	50	55	46	59
DERS-16
M	55.45	55.14	55.14	53.18	51.33	50.02	48.40	45.73	44.82	41.02
SD	11.75	11.70	12.13	11.66	11.84	12.26	11.62	12.27	13.86	14.21
n	66	66	65	57	55	55	50	55	45	57

Note. QIDS-A17-SR = Quick inventory of depressive symptomatology adolescent self-rated version; DERS-16 = Difficulties in emotion regulation scale brief version.

Figure 1. Trajectory of change in depressive symptoms for patients experiencing SGs with 95% confidence intervals for all time points.

Figure 2. Trajectory of change in depressive symptoms for patients experiencing LIIs with 95% confidence intervals for all time points.

Figure 3. DERS-16 for patients experiencing SGs with 95% confidence intervals for all time points.

Figure 4. DERS-16 for patients experiencing LIIs with 95% confidence intervals for all time points.